F
Francisco S. Guimarães
Researcher at National Institute of Standards and Technology
Publications - 2
Citations - 79
Francisco S. Guimarães is an academic researcher from National Institute of Standards and Technology. The author has contributed to research in topics: Cannabidiol & Adverse effect. The author has an hindex of 2, co-authored 2 publications receiving 47 citations. Previous affiliations of Francisco S. Guimarães include University of São Paulo.
Papers
More filters
Journal ArticleDOI
Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?
José Alexandre de Souza Crippa,José Alexandre de Souza Crippa,Jaime Eduardo Cecílio Hallak,Jaime Eduardo Cecílio Hallak,Antonio Waldo Zuardi,Antonio Waldo Zuardi,Francisco S. Guimarães,Francisco S. Guimarães,Vitor Tumas,Vitor Tumas,Rafael G. dos Santos,Rafael G. dos Santos +11 more
TL;DR: CBD was well tolerated, and all three studies reported significant therapeutic effects in non-motor symptoms of PD, however, sample sizes were small and CBD treatment was short, so large-scale RCTs are needed to try to replicate these results and to assess the long-term safety of CBD.
Journal ArticleDOI
Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials
Rafael G. dos Santos,Rafael G. dos Santos,Francisco S. Guimarães,Francisco S. Guimarães,José Alexandre de Souza Crippa,José Alexandre de Souza Crippa,Jaime Eduardo Cecílio Hallak,Jaime Eduardo Cecílio Hallak,Giordano Novak Rossi,Juliana Mendes Rocha,Antonio Waldo Zuardi,Antonio Waldo Zuardi +11 more
TL;DR: Evaluated SAEs related to CBD in RCT are mainly elevated transaminases, convulsion, sedation, lethargy, and upper respiratory tract infections that are related to concomitant clobazam use and should be monitored when using CBD concomitantly with these and other antiepileptic drugs.